# Neurocrine Biosciences Inc: overview

NBIX · Nasdaq · CIK 914475 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nbix.md) · [Financials](/companies/nbix/financials.md) · [Filings](/companies/nbix/filings.md) · [Insiders](/companies/nbix/insiders.md)

Latest reported revenue: [$959.0m](/filings/0000914475-26-000037.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000914475-26-000037).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [622](/filings/0000914475-25-000181.md) | [628 d](/filings/0000914475-26-000007.md) | [573](/filings/0000914475-26-000026.md) | [688](/filings/0000914475-26-000037.md) | [795](/filings/0000914475-25-000181.md) | [806 d](/filings/0000914475-26-000007.md) | [815](/filings/0000914475-26-000026.md) | [959](/filings/0000914475-26-000037.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [29.5%](/filings/0000914475-25-000181.md) | [22.6% d](/filings/0000914475-26-000007.md) | [4.1%](/filings/0000914475-26-000026.md) | [21.2%](/filings/0000914475-26-000037.md) | [30.1%](/filings/0000914475-25-000181.md) | [26.2% d](/filings/0000914475-26-000007.md) | [23.7%](/filings/0000914475-26-000026.md) | [15.8%](/filings/0000914475-26-000037.md) |
| Net margin | % | [20.9%](/filings/0000914475-25-000181.md) | [16.4% d](/filings/0000914475-26-000007.md) | [1.4%](/filings/0000914475-26-000026.md) | [15.6%](/filings/0000914475-26-000037.md) | [26.4%](/filings/0000914475-25-000181.md) | [19.1% d](/filings/0000914475-26-000007.md) | [24.3%](/filings/0000914475-26-000026.md) | [15.1%](/filings/0000914475-26-000037.md) |
| Diluted EPS | $ per share | [1.24](/filings/0000914475-25-000181.md) | not reported | [0.08](/filings/0000914475-26-000026.md) | [1.06](/filings/0000914475-26-000037.md) | [2.04](/filings/0000914475-25-000181.md) | not reported | [1.91](/filings/0000914475-26-000026.md) | [1.39](/filings/0000914475-26-000037.md) |
| Free cash flow | $m | [150 d](/filings/0000914475-25-000181.md) | [235 d](/filings/0000914475-26-000007.md) | [54.1](/filings/0000914475-26-000026.md) | [89.5 d](/filings/0000914475-26-000037.md) | [214 d](/filings/0000914475-25-000181.md) | [386 d](/filings/0000914475-26-000007.md) | [137](/filings/0000914475-26-000026.md) | [129 d](/filings/0000914475-26-000037.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,134](/filings/0000914475-24-000054.md) | [1,489](/filings/0000914475-25-000037.md) | [1,887](/filings/0000914475-26-000007.md) | [2,355](/filings/0000914475-26-000007.md) | [2,861](/filings/0000914475-26-000007.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [9.0%](/filings/0000914475-24-000054.md) | [16.7%](/filings/0000914475-25-000037.md) | [13.3%](/filings/0000914475-26-000007.md) | [24.2%](/filings/0000914475-26-000007.md) | [21.6%](/filings/0000914475-26-000007.md) |
| Net margin | % | [7.9%](/filings/0000914475-24-000054.md) | [10.4%](/filings/0000914475-25-000037.md) | [13.2%](/filings/0000914475-26-000007.md) | [14.5%](/filings/0000914475-26-000007.md) | [16.7%](/filings/0000914475-26-000007.md) |
| Diluted EPS | $ per share | [0.92](/filings/0000914475-24-000054.md) | [1.56](/filings/0000914475-25-000037.md) | [2.47](/filings/0000914475-26-000007.md) | [3.29](/filings/0000914475-26-000007.md) | [4.67](/filings/0000914475-26-000007.md) |
| Free cash flow | $m | [233](/filings/0000914475-24-000054.md) | [323](/filings/0000914475-25-000037.md) | [362](/filings/0000914475-26-000007.md) | [557](/filings/0000914475-26-000007.md) | [749](/filings/0000914475-26-000007.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nbix/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.31bn | 13,711,607 |  | Added +326,000 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $1.09bn | 6,398,674 |  | Added +956,607 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $941.2m | 5,584,707 |  | Added +123,670 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $838.3m | 4,974,083 |  | Added +247,739 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $766.0m | 4,545,339 |  | Added +33,435 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $739.1m | 4,385,598 |  | Added +31,072 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $643.5m | 3,818,037 |  | Reduced −1,120,930 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $393.7m | 2,335,897 |  | Reduced −83,000 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $359.6m | 2,138,777 |  | Added +2,105 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $349.9m | 2,076,260 |  | Reduced −984,310 |

## Recent filings

[All 1,677 filings](/companies/nbix/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-28 | 16:20 ET | [8-K](/filings/0000914475-26-000045.md) | 5.02 Departure or appointment of officers or directors | 0000914475-26-000045 |
| 2026-07-31 | 16:05 ET | [8-K/A](/filings/0001193125-26-328470.md) | 9.01 Financial statements and exhibits | 0001193125-26-328470 |
| 2026-07-31 | 21:22 ET | [10-Q](/filings/0000914475-26-000037.md) | Quarterly report, period 2026-06-30 | 0000914475-26-000037 |
| 2026-07-30 | 16:02 ET | [8-K](/filings/0000914475-26-000035.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000914475-26-000035 |
| 2026-05-28 | 16:01 ET | [8-K](/filings/0000914475-26-000029.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000914475-26-000029 |
| 2026-05-18 | 09:04 ET | [8-K](/filings/0001193125-26-228013.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-228013 |
| 2026-05-05 | 16:02 ET | [10-Q](/filings/0000914475-26-000026.md) | Quarterly report, period 2026-03-31 | 0000914475-26-000026 |
| 2026-05-05 | 16:02 ET | [8-K](/filings/0000914475-26-000025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000914475-26-000025 |
| 2026-04-15 | 16:15 ET | [DEF 14A](/filings/0000914475-26-000015.md) | Proxy statement, period 2026-04-15 | 0000914475-26-000015 |
| 2026-04-06 | 07:35 ET | [8-K](/filings/0001193125-26-142904.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-142904 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000914475-26-000007.md), filed Feb 11, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/775715fc-d5bd-4b07-ac49-2be51c2fdb67)

## About the filer

- CIK: 914475
- Tickers: NBIX
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:30 ET. No prices; not investment advice.